Method for treating a homeostasis-related disease or glaucoma by administering a 1,2,3,4-tetrahyroquinoxaline compound

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8569493
APP PUB NO 20120129866A1
SERIAL NO

13364680

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method for preventing or treating a metabolic disorder, an inflammatory disease, an autoimmune disease, an allergic disease, a central nervous system disease, a cardiovascular disease, a homeostasis-related disease or glaucoma, involving administering a compound or a salt thereof, the compound having the following formula (1):

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SANTEN PHARMACEUTICAL CO LTD9-19 SHIMOSHINJO 3-CHOME HIGASHIYODOGAWA-KU OSAKA-SHI OSAKA 533-8651

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kato, Masatomo Ikoma, JP 27 100
Kobayashi, Sachiko Ikoma, JP 62 489
Matsuda, Mamoru Ikoma, JP 17 101
Mori, Toshiyuki Ikoma, JP 55 417
Nagatsuka, Masato Ikoma, JP 14 81
Takai, Miwa Ikoma, JP 17 108

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 29, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00